Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 5/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779111 | 0.92 | MAPK1 (0.33) | MAPK1NAMPTHRH4GRM5KCNH2 | |
| SCHEMBL23779050 | 0.92 | MAPK1 (0.33) | MAPK1NAMPTGRM5RAF1BRAF | |
| SCHEMBL23779084 | 0.85 | MAPK10 (0.39) | MMP9NAMPTHRH4 | |
| SCHEMBL23779059 | 0.83 | HRH4 (0.46) | NAMPTHRH4GRM5 | |
| SCHEMBL23779053 | 0.83 | POLB (0.47) | NAMPTHRH4 | |
| SCHEMBL23779131 | 0.79 | HRH4 (0.36) | MMP9HRH4GRM5KCNH2 | |
| SCHEMBL23779058 | 0.78 | AKR1C3 (0.47) | HRH4 | |
| SCHEMBL23779042 | 0.78 | POLB (0.38) | NAMPTHRH4GRM5KCNH2 | |
| SCHEMBL23779123 | 0.78 | POLB (0.51) | NAMPTHRH4 | |
| SCHEMBL22395879 | 0.78 | NPY5R (0.40) | MMP9GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-17 | — | — | US | disclosed |
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-17 | — | — | US | disclosed |
| EP-3873910-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | MMP9 2854/4885MAPK1 2605/4885NAMPT 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.